{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T14:57:38Z","timestamp":1710255458232},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.2515\/therapie\/2011018","type":"journal-article","created":{"date-parts":[[2011,6,3]],"date-time":"2011-06-03T11:11:49Z","timestamp":1307099509000},"page":"135-138","source":"Crossref","is-referenced-by-count":6,"title":["Pulmonary Arterial Hypertension and Benfluorex: 5 Case Reports"],"prefix":"10.1016","volume":"66","author":[{"given":"Emmanuelle","family":"Bondon-Guitton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gr\u00e9goire","family":"Pr\u00e9v\u00f4t","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Didier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Louis","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.2515\/therapie\/2011018_bb0005","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1472-8206.2006.00441.x","article-title":"Valvular heart disease in a patient taking benfluorex","volume":"20","author":"Noize","year":"2006","journal-title":"Fundam Clin Pharmacol"},{"key":"10.2515\/therapie\/2011018_bb0010","first-page":"215","article-title":"Valvular heart disease associated with benfluorex","volume":"56","author":"Rafel Ribera","year":"2003","journal-title":"Rev Esp Cardiol"},{"key":"10.2515\/therapie\/2011018_bb0015","unstructured":"Rappel des sp\u00e9cialit\u00e9s \u00e0 base de benfluorex - Afssaps : Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9. http:\/\/www.afssaps.fr\/Infos-de-securite\/Retraits-de-lots-et-de-produits\/Rappel-des-specialites-a-base-de-benfluorex"},{"key":"10.2515\/therapie\/2011018_bb0020","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: definitions, diagnosis, and management","volume":"356","author":"Edwards","year":"2000","journal-title":"Lancet"},{"key":"10.2515\/therapie\/2011018_bb0025","first-page":"5551","article-title":"International Conference on Harmonisation; guidance on Addendum to E2C Clinical Safety Data Management: periodic safety update reports for marketed drugs","author":"Food and Drug Administration, HHS","year":"2004","journal-title":"Fed Regist"},{"key":"10.2515\/therapie\/2011018_bb0030","first-page":"111","article-title":"Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France","volume":"40","author":"B\u00e9gaud","year":"1985","journal-title":"Therapie"},{"key":"10.2515\/therapie\/2011018_bb0035","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2165\/00002018-200528080-00007","article-title":"Trends in spontaneous adverse drug reaction reports to the French pharmacovigilance system (1986-2001)","volume":"28","author":"Thiessard","year":"2005","journal-title":"Drug Saf"},{"key":"10.2515\/therapie\/2011018_bb0040","doi-asserted-by":"crossref","first-page":"216","DOI":"10.7326\/0003-4819-107-2-216","article-title":"Primary pulmonary hypertension. A national prospective study","volume":"107","author":"Rich","year":"1987","journal-title":"Ann Intern Med"},{"key":"10.2515\/therapie\/2011018_bb0045","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1001\/jama.288.13.1588","article-title":"Rates of spontaneous reporting of adverse drug reactions in France","volume":"288","author":"B\u00e9gaud","year":"2002","journal-title":"JAMA"},{"key":"10.2515\/therapie\/2011018_bb0050","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s002280050314","article-title":"Attitude survey of adverse drug-reaction reporting by health care professionals across the European Union. The European Pharmacovigilance Research Group","volume":"52","author":"Belton","year":"1997","journal-title":"Eur J Clin Pharmacol"},{"key":"10.2515\/therapie\/2011018_bb0055","series-title":"Pharmacovigilance","author":"Mann","year":"2002"},{"key":"10.2515\/therapie\/2011018_bb0060","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00104807","article-title":"Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases","volume":"31","author":"Souza","year":"2008","journal-title":"Eur Respir J"},{"key":"10.2515\/therapie\/2011018_bb0065","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/0140-6736(92)90129-Q","article-title":"Pulmonary hypertension and dexfenfluramine","volume":"339","author":"Atanassoff","year":"1992","journal-title":"Lancet"},{"key":"10.2515\/therapie\/2011018_bb0070","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/0140-6736(92)90129-Q","article-title":"Pulmonary hypertension and dexfenfluramine","volume":"339","author":"Roche","year":"1992","journal-title":"Lancet"},{"key":"10.2515\/therapie\/2011018_bb0075","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJM199608293350901","article-title":"Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group","volume":"335","author":"Abenhaim","year":"1996","journal-title":"N Engl J Med"},{"key":"10.2515\/therapie\/2011018_bb0080","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/rr181","article-title":"Anorexigen-induced pulmonary hypertension and the serotonin (5-HT) hypothesis: lessons for the future in pathogenesis","volume":"3","author":"Eddahibi","year":"2002","journal-title":"Respir Res"},{"key":"10.2515\/therapie\/2011018_bb0085","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0002-9343(99)80156-9","article-title":"Increased plasma serotonin in primary pulmonary hypertension","volume":"99","author":"Herv\u00e9","year":"1995","journal-title":"Am J Med"},{"issue":"suppl","key":"10.2515\/therapie\/2011018_bb0090","doi-asserted-by":"crossref","first-page":"97S","DOI":"10.1378\/chest.121.3_suppl.97S","article-title":"Hyperplasia of pulmonary artery smooth muscle cells is causally related to overexpression of the serotonin transporter in primary pulmonary hypertension","volume":"121","author":"Eddahibi","year":"2002","journal-title":"Chest"},{"key":"10.2515\/therapie\/2011018_bb0095","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1172\/JCI200112805","article-title":"Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension","volume":"108","author":"Eddahibi","year":"2001","journal-title":"J Clin Invest"},{"key":"10.2515\/therapie\/2011018_bb0100","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1001\/archinte.158.11.1278","article-title":"The \"phen-pro\" diet drug combination is not associated with valvular heart disease","volume":"158","author":"Griffen","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.2515\/therapie\/2011018_bb0105","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1183\/09031936.00086308","article-title":"Fenfluramine-like cardiovascular sideeffects of benfluorex","volume":"33","author":"Boutet","year":"2009","journal-title":"Eur Respir J"},{"key":"10.2515\/therapie\/2011018_bb0110","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1164\/rccm.200510-1668OC","article-title":"Pulmonary arterial hypertension in France: results from a national registry","volume":"173","author":"Humbert","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.2515\/therapie\/2011018_bb0115","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/sj.ijo.0801020","article-title":"Dose-effect of fenfluramine use on the severity of valvular heart disease among fen-phen patients with valvulopathy","volume":"23","author":"Li","year":"1999","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.2515\/therapie\/2011018_bb0120","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1741-7015-6-34","article-title":"Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals","volume":"6","author":"Dahl","year":"2008","journal-title":"BMC Med"},{"key":"10.2515\/therapie\/2011018_bb0125","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1161\/01.CIR.102.23.2836","article-title":"Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications","volume":"102","author":"Rothman","year":"2000","journal-title":"Circulation"},{"key":"10.2515\/therapie\/2011018_bb0130","doi-asserted-by":"crossref","first-page":"5S","DOI":"10.1016\/j.jacc.2004.02.037","article-title":"Clinical classification of pulmonary hypertension","volume":"43","author":"Simonneau","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.2515\/therapie\/2011018_bb0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010128","article-title":"Benfluorex and unexplained valvular heart disease: a case-control study","volume":"5","author":"Frachon","year":"2010","journal-title":"PLoS ONE"},{"issue":"12","key":"10.2515\/therapie\/2011018_bb0140","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1002\/pds.2044","article-title":"Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus","volume":"19","author":"Weill","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716307533?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716307533?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T03:43:56Z","timestamp":1554263036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595716307533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S0040595716307533"],"URL":"https:\/\/doi.org\/10.2515\/therapie\/2011018","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}